Compare WFF & HIND Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | WFF | HIND |
|---|---|---|
| Founded | 1984 | 2017 |
| Country | Malaysia | United States |
| Employees | 142 | 18 |
| Industry | Miscellaneous manufacturing industries | |
| Sector | Consumer Discretionary | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 17.9M | 15.2M |
| IPO Year | N/A | 2016 |
| Metric | WFF | HIND |
|---|---|---|
| Price | $2.38 | $2.24 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $15.00 |
| AVG Volume (30 Days) | ★ 52.1K | 15.1K |
| Earning Date | 05-24-2026 | 05-20-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.18 | $1.75 |
| 52 Week High | $3.15 | $12.87 |
| Indicator | WFF | HIND |
|---|---|---|
| Relative Strength Index (RSI) | 50.97 | 49.97 |
| Support Level | $0.38 | $1.99 |
| Resistance Level | $3.08 | $2.35 |
| Average True Range (ATR) | 0.26 | 0.09 |
| MACD | -0.06 | 0.00 |
| Stochastic Oscillator | 61.74 | 50.00 |
WF Holding Ltd is a manufacturer of FRP products based in Malaysia. It has been providing high-quality and durable FRP products to various industries, including, among others, chemical processing, water and wastewater treatment, and power generation. Its products range from tanks, pipes, ducts, gratings, and other custom-made FRP products. Its manufacturing capabilities allow the company to design and fabricate products that meet the specific needs of its clients, ensuring high-quality and reliable performance. Geographically, the company generates the majority of its revenue from Australia.
Vyome Holdings Inc is a clinical-stage specialty pharmaceutical company working to treat immune-inflammatory and rare diseases of unmet need with next-generation therapeutic solutions. Its product candidates are: VT-1953, a topical gel that is being developed to treat signs and symptoms of malignant fungating wounds in cancer; VT-1908, a repurposed immune modulator to treat steroid-sparing anterior uveitis; and VB1953, which is being developed to treat moderate to severe acne. Vyome has also commercialized two novel reformulated topical anti-fungal products based on the technology platform of Molecular Replacement Therapeutics (MRT) in India: a dandruff lotion and shampoo. It operates in two segments: pharmaceutical products, which generate the maximum revenue, and biotechnology.